Parametric Portfolio Associates’s CytomX Therapeutics CTMX Stock Holding History

Parametric Portfolio Associates’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$65K	Sell	24,371 -17,390	-42%	-$66.8K	﹤0.01%	3608
2021 Q4	$181K	Buy	41,761 +353	+0.9%	+$2.07K	﹤0.01%	3444
2021 Q3	$211K	Buy	41,408 +2,209	+6%	+$11.8K	﹤0.01%	3416
2021 Q2	$248K	Sell	39,199 -20,621	-34%	-$161K	﹤0.01%	3330
2021 Q1	$462K	Sell	59,820 -38,841	-39%	-$307K	﹤0.01%	3535
2020 Q4	$646K	Sell	98,661 -121,471	-55%	-$868K	﹤0.01%	3253
2020 Q3	$1.46M	Sell	220,132 -31,343	-12%	-$232K	﹤0.01%	2686
2020 Q2	$2.1M	Buy	+251,475	New	+$2.34M	﹤0.01%	2477

Other funds holding CTMX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Parametric Portfolio Associates's CTMX Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its CytomX Therapeutics (CTMX) stake by 42% in Q1 2022, selling an estimated $66.8K and leaving 24,371 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #3608.

Parametric Portfolio Associates first reported a position in CTMX in Q2 2020 and has held it in 8 quarters since. The position peaked at $2.1M in Q2 2020. 119 funds tracked by Wall St. Rank hold CTMX as of Q1 2022.

Parametric Portfolio Associates held 24,371 shares of CytomX Therapeutics worth $65K as of Q1 2022.
Parametric Portfolio Associates sold 17,390 CytomX Therapeutics shares in Q1 2022, an estimated $66.8K.
CytomX Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3608 holding.
Parametric Portfolio Associates first reported a position in CytomX Therapeutics in Q2 2020 and has held it in 8 quarters since.
Parametric Portfolio Associates's CytomX Therapeutics position peaked at $2.1M in Q2 2020.
119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.